MedDataX Logo

Second Clinical Evaluation of THERANOVA-500 Dialyzer in Chronic Hemodialysis (HD)

NCT ID: NCT03618368

Last Updated: 2020-11-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-25

Study Completion Date

2021-06-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Single blinded randomized controlled trial comparing Expanded Hemodialysis (HDx) using THERANOVA-500 dialyzer versus conventional hemodialysis (HD) using REVACLEAR-400 dialyzer in chronic hemodialysis patients over a 6-week intervention period. Primary endpoint is post-hemodialysis recovery time. Secondary endpoints are six pre-dialysis biomarker levels (b2-microglobuline, procalcitonine, free light chains (gamma-lambda), IL-6, CRP) and three Quality of Life (QoL)(adapted KDQoL-SF questionnaire, EQ-5D, and rESAS).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized controlled trial involving 70 subjects divided in 4 groups: 25 single blinded subjects using THERANOVA-500 dialyzer enabling Expanded Hemodialysis (HDx) ; 25 single blinded subjects using REVACLEAR-400 dialyzer enabling conventional hemodialysis (HD); 10 non-blinded subjects using THERANOVA-500 enabling Expanded Hemodialysis (HDx) and 10 non-blinded subjects using REVACLEAR-400 dialyzer enabling conventional hemodialysis (HD) for their chronic hemodialysis treatments over an active intervention period of 6 weeks. All subjects are to be dialyzed using REVACLEAR-400 enabling conventional hemodialysis (HD) for two weeks prior and for two weeks after the intervention period.

Primary endpoint is mean post-hemodialysis recovery time (as reported by subjects once weekly) between groups (THERANOVA-500 vs REVACLEAR-400) (all subjects) during the 6-week intervention period.

Secondary endpoints are:

1. Post-hemodialysis recovery time change (mean of 2-week pre and 2-week post intervention period compared to mean during 6-week intervention period)(mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects),
2. Post-hemodialysis recovery time difference (mean between blinded and non-blinded THERANOVA-500 treated subjects during the 6-week intervention period,
3. Post-hemodialysis recovery time difference (mean between blinded and non-blinded REVACLEAR-400 treated subjects during the 6-week intervention period),
4. Post-hemodialysis recovery time difference mean gap between secondary endpoints 2 and 3,
5. Percentage of subjects who report no (zero) recovery time (mean THERANOVA-500 vs mean REVACLEAR-400) during 6-week intervention period (all subjects),
6. Pre and post 6-week intervention period pre-dialysis difference levels of beta-2 microglobulin (mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(in nmol/L),
7. Pre and post 6-week intervention period pre-dialysis difference levels of procalcitonin (mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(in ng/ml),
8. Pre and post 6-week intervention period pre-dialysis difference levels of free light chains (gamma and lambda)(mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(in mg/L),
9. Pre and post 6-week intervention period pre-dialysis difference levels of interleukine-6 (mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(in pg/ml),
10. Pre and post 6-week intervention period pre-dialysis difference levels of C reactive protein (CRP)(mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(in mg/L),
11. Quality of life change (pre and at 2 weeks of intervention period) (mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(assessed by adapted KDQoL-SF questionnaire)(max score 130),
12. Quality of life change (pre and at 4 weeks of intervention period) (mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects) assessed by adapted KDQoL-SF questionnaire)(max score 130),
13. Quality of life change (at 4 weeks of intervention period and week 8 of study)(mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects) assessed by adapted KDQoL-SF (max score 130),
14. Quality of life change (pre and at 2 weeks of intervention period)(mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(assessed by EQ-5D questionnaire)(max score 125),
15. Quality of life change (pre and at 4 weeks of intervention period)(mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(assessed by EQ-5D questionnaire)(max score 125),
16. Quality of life change (at 4 weeks of intervention period and week 8 of study)(mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(assessed by EQ-5D questionnaire (max score 125),
17. Quality of life change (pre and at 2 weeks of intervention period (mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(assessed by rESAS)(max score 100),
18. Quality of life change (pre and at 4 weeks of intervention period (mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(assessed by rESAS)(max score 100),
19. Quality of life change (at 4 weeks of intervention period and week 8 of study)(mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(assessed by rESAS)(max score 100),
20. Subjects's QoL questionnaire fill preference (adapted KD QoL-SF vs EQ-5D vs rESAS) at study week 8.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End Stage Renal Disease on Dialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

1 blinded group on THERANOVA-500 dialyzer (Expanded Hemodialysis (HDx))

1 blinded group on REVACLEAR-400 dialyzer (conventional hemodialysis (HD))

1 non-blinded group on THERANOVA-500 dialyzer (Expanded Hemodialysis (HDx))

1 non-blinded group on REVACLEAR-400 dialyzer (conventional hemodialysis (HD))
Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants
blinded group: as dialyzers are almost identical except for their labels, blinding is achieved by masking dialyzer labels.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blinded THERANOVA-500 dialyzer

This group of 25 subjects is dialyzed with masked THERANOVA-500 dialyzer enabling Expanded Hemodialysis (HDx) therapy.

Group Type EXPERIMENTAL

THERANOVA-500 dialyzer

Intervention Type DEVICE

THERANOVA-500 dialyzer is a hemofilter that enables Expanded Hemodialysis (HDx) therapy.

Blinded REVACLEAR-400 dialyzer

This group of 25 subjects is dialyzed with masked REVACLEAR-400 dialyzer enabling conventional hemodialysis (HD).

Group Type PLACEBO_COMPARATOR

REVACLEAR-400 dialyzer

Intervention Type DEVICE

REVACLEAR-400 dialyzer is an usual hemofilter that enables conventional hemodialysis (HD).

Unblinded THERANOVA-500 dialyzer

This group of 10 subjects is dialyzed with unmasked THERANOVA-500 dialyzer which enables Expanded Hemodialysis (HDx) therapy.

Group Type EXPERIMENTAL

THERANOVA-500 dialyzer

Intervention Type DEVICE

THERANOVA-500 dialyzer is a hemofilter that enables Expanded Hemodialysis (HDx) therapy.

Unblinded REVACLEAR-400 dialyzer

This group of 10 subjects is dialyzed with unmasked REVACLEAR-400 dialyzer which enables conventional hemodialysis (HD).

Group Type PLACEBO_COMPARATOR

REVACLEAR-400 dialyzer

Intervention Type DEVICE

REVACLEAR-400 dialyzer is an usual hemofilter that enables conventional hemodialysis (HD).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

THERANOVA-500 dialyzer

THERANOVA-500 dialyzer is a hemofilter that enables Expanded Hemodialysis (HDx) therapy.

Intervention Type DEVICE

REVACLEAR-400 dialyzer

REVACLEAR-400 dialyzer is an usual hemofilter that enables conventional hemodialysis (HD).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age greater than 18 years, all genders.
* HD at DrGLDUHC for more than 3 months, 3 times/week schedule, and using REVACLEAR-400.
* Good vascular access (blood flow (Qb) \> 300 during entire previous 6 HD sessions, no per-HD alteplase treatments used over the last 2 weeks, routine alteplase-lock allowed)
* Signed informed consent
* Likely to be able to participate for the duration of the clinical evaluation (no trips, no elective procedures, no transfer to another dialysis modality or HD facility, etc).
* Able to fill questionnaires, staff assistance allowed.

Exclusion Criteria

* HD more than 3 times/week
* HD on other dialyzers than REVACLEAR-400
* Poor vascular access (from staff and Nephrologists' evaluation)
* No consent or unable to answer questionnaires even with staff assistance.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Réseau de Santé Vitalité Health Network

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marc Dorval, MD,MPH,MBA

Role: PRINCIPAL_INVESTIGATOR

Dr Georges-L.-Dumont University Hospital Centre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dr Georges-L.-Dumont University Hospital Centre

Moncton, New Brunswick, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NEP2018-01

Identifier Type: -

Identifier Source: org_study_id